title: [Effects of isosorbide-5-mononitrate on clinical condition, bicycle ergometry results, endothelium-dependent vasodilation in patients with ischemic heart disease with stable effort angina].
abstract: OBJECTIVE
  Assessment of efficacy of treatment of coronary heart disease (CHD) patients suffering from stable effort angina of functional class II-III with the drug isosorbide-5-mononitrate Mono Mac 50 depo (MM 50 D).
  
  
  METHODS
  Clinical indices, exercise tolerance, endothelial function (the study of brachial artery in reactive hyperemia and sublingual intake of nitroglycerin) were studied in 30 patients with stable angina FC II-III before the treatment, 1 and 3 months after the treatment.
  
  
  RESULTS
  MM 50D significantly widens diameter of the brachial artery (by 11.6%), lowers nitroglycerin-dependent vasodilation (from 16% to 10.4% in a month and to 10.2% in 3 months) and blood flow speed in reactive hyperemia. An absolute increment of the brachial artery diameter in reactive hyperemia test remained unchanged. The ratio flow-dependent vasodilation/nitroglycerin-dependent vasodilation increased in the course of therapy from 0.67 to 0.91. The drug produced clinical improvement (anginal attacks rate diminished by 70 and 85%, respectively) and increased exercise tolerance (the threshold performance rose by 28%, total load time--by 30%).
  
  
  CONCLUSIONS
  It is important to use complex assessment of hemodynamic component of endothelial function in the treatment with nitrates.
authors.forename: S S
authors.initials: SS
authors.lastname: Kazachkina
authors.forename: T V
authors.initials: TV
authors.lastname: Balakhonova
authors.forename: V P
authors.initials: VP
authors.lastname: Lupanov
authors.forename: O A
authors.initials: OA
authors.lastname: Pogorelova
authors.forename: A N
authors.initials: AN
authors.lastname: Rogoza
authors.forename: V G
authors.initials: VG
authors.lastname: Naumov
mesh_terms: D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000145:classification / Q000150:complications* / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D001783:Blood Flow Velocity / Q000187:drug effects; D001916:Brachial Artery / Q000000981:diagnostic imaging / Q000187:drug effects / Q000503:physiopathology; D004730:Endothelium, Vascular / Q000000981:diagnostic imaging / Q000187:drug effects / Q000503:physiopathology*; D005080:Exercise Test; D017079:Exercise Tolerance / Q000187:drug effects; D005500:Follow-Up Studies; D006801:Humans; D007548:Isosorbide Dinitrate / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D005996:Nitroglycerin / Q000627:therapeutic use; D005082:Physical Exertion; D013997:Time Factors; D016896:Treatment Outcome; D014463:Ultrasonography; D014664:Vasodilation / Q000187:drug effects / Q000502:physiology; D014665:Vasodilator Agents / Q000627:therapeutic use*
chemical_list: D014665:Vasodilator Agents; D005996:Nitroglycerin; D007548:Isosorbide Dinitrate; C030397:isosorbide-5-mononitrate